Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Wegovy is made by Novo Nordisk A/S, the same Danish pharmaceutical company that manufactures Ozempic and Rybelsus.
- The active ingredient is semaglutide, identical to the molecule in Ozempic. The difference is the FDA-approved indication and the available dose strengths.
- Wegovy was approved in June 2021 for chronic weight management in adults with obesity. The indication expanded to adolescents in December 2022 and to cardiovascular risk reduction in March 2024.
- The pivotal weight-loss trial was STEP 1 (Wilding et al., NEJM 2021); the pivotal cardiovascular trial was SELECT (Lincoff et al., NEJM 2023).
- Wegovy is not a generic and no FDA-approved generic semaglutide exists. Compounded semaglutide is a distinct product not made by Novo Nordisk.
Direct answer
Wegovy is manufactured by Novo Nordisk A/S, headquartered in Bagsvaerd, Denmark. It contains semaglutide, the same active ingredient as Ozempic and Rybelsus. Wegovy is the brand name Novo Nordisk uses for semaglutide approved for chronic weight management, with maximum dosing of 2.4 mg weekly. Ozempic is the brand name used for the same molecule when prescribed for type 2 diabetes, with maximum dosing of 2.0 mg weekly. One company, one molecule, two indication-specific brands.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Table of contents
- The simple answer and the longer one
- Why one molecule has two brand names
- The Wegovy development timeline
- What the FDA actually approved
- How Wegovy differs from Saxenda within the same company
- Where Wegovy is manufactured
- What the SELECT trial added
- The compounded semaglutide question
- Pricing, payers, and access
- The competitive picture vs Zepbound
- FAQ
- Sources
The simple answer and the longer one
The simple answer: Wegovy is made by Novo Nordisk.
The longer answer asks why the question is even interesting. Most patients first encounter "Wegovy" through their prescriber, an insurance pre-authorization, or a pharmacy counter. The name on the box does not match the name of the molecule. The same molecule appears in another product (Ozempic) sold by the same company at a different dose for a different indication. And a third product (Rybelsus) from the same company contains the same molecule in oral form. Knowing that one company sits behind all three changes how to think about supply, pricing, and litigation.
Why one molecule has two brand names
The two-brand structure is a deliberate regulatory and commercial strategy.
- Indication clarity. Each FDA-approved indication has its own labeling, package insert, and post-marketing requirements. Selling the same molecule under different brand names for different indications keeps the labels separate and the prescribing simpler.
- Dose differences. Wegovy is available at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg weekly. Ozempic is available at 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg weekly. The higher maximum dose of Wegovy reflects the STEP trial program for obesity.
- Payer logic. Coverage policies and formularies treat obesity and diabetes prescriptions differently. Separate brands let payers process claims under the relevant policy.
- Marketing. Each brand can be promoted to the appropriate prescriber audience and patient population without confusing the indication.
The strategy is common in pharmaceutical practice. Examples include bupropion sold as Wellbutrin for depression and Zyban for smoking cessation, or fluoxetine sold as Prozac for depression and Sarafem for premenstrual dysphoric disorder.
The Wegovy development timeline
| Year | Milestone |
|---|---|
| 2012-2017 | Phase 2 and 3 development of semaglutide for diabetes, leading to Ozempic. |
| December 2017 | FDA approves Ozempic for type 2 diabetes. |
| 2018-2021 | STEP program (STEP 1 through STEP 8) evaluates semaglutide 2.4 mg weekly for chronic weight management. |
| June 4, 2021 | FDA approves Wegovy for chronic weight management in adults. |
| December 2022 | FDA expands Wegovy approval to adolescents aged 12 and older with obesity, based on STEP TEENS. |
| March 2024 | FDA approves an updated Wegovy indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, based on SELECT. |
| February 2025 | FDA removes semaglutide from the drug shortage list. |
What the FDA actually approved
The Wegovy label, as of May 2026, includes three principal indications:
- Chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.
- Chronic weight management in adolescents 12 years and older with obesity defined as BMI at or above the 95th percentile for age and sex.
- Cardiovascular risk reduction in adults with established cardiovascular disease and either overweight or obesity, to reduce the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
Standard contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and known serious hypersensitivity to semaglutide or any product component.
How Wegovy differs from Saxenda within the same company
Both Wegovy and Saxenda are Novo Nordisk weight-management products. They share an FDA-approved class but differ in molecule and dosing.
| Feature | Wegovy | Saxenda |
|---|---|---|
| Active ingredient | Semaglutide | Liraglutide |
| Dosing | Once weekly subcutaneous | Once daily subcutaneous |
| Maximum dose | 2.4 mg weekly | 3.0 mg daily |
| Approval year | 2021 | 2014 |
| Adolescent indication | Yes (12+) | Yes (12+) |
| Average trial weight loss | ~14.9% over 68 weeks (STEP 1) | ~5-8% over 56 weeks (SCALE trials) |
The same manufacturer offering two GLP-1 weight-management products at different efficacy and dosing tiers reflects the company's century of GLP-1 and peptide development.
Where Wegovy is manufactured
The semaglutide active pharmaceutical ingredient is produced principally at Novo Nordisk's Danish facilities. Fill-finish operations, which involve filling the active ingredient into pens and other delivery devices, are distributed across the company's global network.
For the US market, the Clayton, North Carolina facility is the major fill-finish site. Novo Nordisk announced substantial expansion of US fill-finish capacity during 2023 through 2025, in response to demand that drove the semaglutide shortage.
What the SELECT trial added
SELECT (Lincoff et al., New England Journal of Medicine, 2023) tested semaglutide 2.4 mg weekly against placebo in adults with cardiovascular disease and overweight or obesity but without type 2 diabetes. Approximately 17,600 patients were followed for a mean of just over three years.
The headline finding: a statistically significant reduction in the composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo. The relative risk reduction was approximately 20 percent in the trial.
SELECT supported the March 2024 FDA approval of an expanded Wegovy indication for cardiovascular risk reduction. The trial substantially increased payer interest in Wegovy coverage by reframing obesity treatment as part of cardiovascular risk management rather than a separate cosmetic category.
The compounded semaglutide question
During the 2022 through early 2025 semaglutide shortage, the FDA's shortage-tolerance rules allowed state-licensed compounding pharmacies to compound semaglutide for individual patients under specific conditions. Compounded semaglutide proliferated through telehealth platforms and medical spas.
Key facts to keep clear:
- Novo Nordisk does not make compounded semaglutide.
- Compounded semaglutide is not FDA-approved.
- The shortage-tolerance basis for compounding narrowed substantially when the FDA removed semaglutide from the shortage list in February 2025.
- Novo Nordisk has filed numerous lawsuits against compounding pharmacies, clinics, and telehealth platforms it accused of selling compounded GLP-1 products inappropriately.
Compounded products are a distinct category and should never be presented as equivalent to Wegovy or Ozempic.
Pricing, payers, and access
Wegovy carries a high US list price, with substantial differences between cash, commercial insurance, Medicare Part D, and Medicaid coverage. The picture as of May 2026 includes:
- Commercial coverage that varies widely by employer; some plans cover Wegovy after step therapy with other agents, others exclude obesity medications.
- Medicare Part D coverage that expanded after the March 2024 cardiovascular indication, since Part D may cover GLP-1s for cardiovascular risk reduction in eligible patients.
- Manufacturer savings programs that reduce cost for commercially insured patients meeting eligibility criteria.
- Cash list prices that remain among the highest in the global market for semaglutide.
Patients should verify current coverage directly through their insurer and consult their prescriber for clinically appropriate options if Wegovy is not covered.
The competitive picture vs Zepbound
The major clinical alternative to Wegovy in the US is Zepbound (tirzepatide), made by Eli Lilly.
| Wegovy | Zepbound | |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Active ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | GIP and GLP-1 receptor co-agonist |
| Pivotal trial weight loss | ~14.9% (STEP 1 at 2.4 mg) | ~22.5% (SURMOUNT-1 at 15 mg) |
| Dosing | Once weekly | Once weekly |
| Cardiovascular indication | Yes (Wegovy, March 2024) | Pending (SURMOUNT-MMO data readout) |
Choosing between Wegovy and Zepbound is a clinical decision that depends on insurance coverage, comorbidities, prior medication experience, and tolerability. Both are options for many patients meeting FDA criteria for chronic weight management.
The contrary view: limitations of trial-average outcomes
For balance, the STEP 1 average of ~14.9 percent weight loss is a group-level statistic. Individual patient outcomes vary considerably.
- Some patients lose substantially more than 20 percent.
- Some lose less than 5 percent ("limited responders").
- Trial enrollees received intensive lifestyle support that not all real-world patients receive.
- Discontinuation in trials reduces but does not eliminate the average effect; real-world adherence may be lower.
Patients evaluating Wegovy should set expectations based on the range of outcomes, not the single headline number.
Compounded medication note for this topic
For Who Makes Wegovy? Novo Nordisk's Obesity-Indication Brand of Semaglutide, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.
FAQ
Who makes Wegovy?
Novo Nordisk A/S, the Danish pharmaceutical company also responsible for Ozempic, Rybelsus, Saxenda, and Victoza.
Is Wegovy a generic?
No. Wegovy is the brand name for FDA-approved semaglutide for chronic weight management. No FDA-approved generic semaglutide exists.
Is Wegovy the same drug as Ozempic?
Both contain semaglutide. They differ in approved indication (obesity vs diabetes) and in maximum dose (2.4 mg weekly for Wegovy, 2.0 mg weekly for Ozempic).
When was Wegovy approved?
June 4, 2021, for adults. December 2022 for adolescents 12 and older. March 2024 for cardiovascular risk reduction in eligible adults.
Where is Wegovy made?
Active ingredient production is concentrated in Denmark; US fill-finish work is performed at Novo Nordisk's Clayton, North Carolina facility.
What is the SELECT trial?
The cardiovascular outcomes trial of semaglutide 2.4 mg in patients with cardiovascular disease and overweight or obesity but not diabetes, published by Lincoff et al. in 2023. SELECT supported the March 2024 cardiovascular indication.
Is compounded semaglutide made by Novo Nordisk?
No. Compounded semaglutide is prepared by state-licensed compounding pharmacies under individual prescriptions and is not FDA-approved.
Why is Wegovy more expensive in the US than elsewhere?
US pricing reflects patent-protected exclusivity, rebate structures, and limited price negotiation. Other developed markets negotiate directly with manufacturers and pay less.
Does Wegovy come in pills?
No. Wegovy is a once-weekly subcutaneous injection. Novo Nordisk's oral semaglutide is sold as Rybelsus for type 2 diabetes; an oral semaglutide for obesity is in development.
Who competes with Wegovy?
Zepbound (tirzepatide), made by Eli Lilly, is the major US competitor for chronic weight management.
Related guides
- Who Makes Ozempic? Inside Novo Nordisk, the Danish Company Behind the GLP-1 Era
- Where Is Ozempic Manufactured? Mapping Novo Nordisk's Global Supply Chain
- How Long for Semaglutide to Work? The Pharmacology of the Molecule, Brand or Compounded
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
Sources
- US Food and Drug Administration. Wegovy Prescribing Information.
- US Food and Drug Administration. Approval letter, Wegovy for chronic weight management. June 4, 2021.
- US Food and Drug Administration. Expanded indication for adolescents. December 2022.
- US Food and Drug Administration. Cardiovascular indication approval. March 2024.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. New England Journal of Medicine. 2020. (Context for adolescent GLP-1 use.)
- Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). New England Journal of Medicine. 2022.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Novo Nordisk. Annual Report 2024.
- US Food and Drug Administration. Drug Shortages Database. Semaglutide resolution, February 21, 2025.
- American Diabetes Association. Standards of Care in Diabetes, 2025 edition (obesity management section).
Footer disclaimers
Platform Disclaimer. FormBlends is an independent digital health platform connecting patients with licensed clinicians and US-based pharmacies. We are not affiliated with Novo Nordisk. This article is educational and not a substitute for clinical care.
Compounded Medication Notice. Compounded semaglutide is not FDA-approved and is not manufactured by Novo Nordisk. It is prepared by state-licensed compounding pharmacies under individual prescriptions and is distinct from Wegovy.
Results Disclaimer. Trial averages cited above reflect group-level outcomes. Individual results vary by diet, activity, baseline weight, adherence, and physiological response.
Trademark Notice. Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by either manufacturer.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →